Compare Natera Inc. Common Stock (NTRA) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Royal Bank of Canada — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Royal Bank of Canada trades at $193.8 (market cap $268.76B). The key difference: Royal Bank of Canada is far larger — about 4.7× Natera Inc. Common Stock's market cap, and Royal Bank of Canada pays a 2.61% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Royal Bank of Canada for 48 Days on average.
| NTRA | RY | |
|---|---|---|
Market Cap | $57.03B | $268.76B |
Volume | 1,131,157 | 1,509,016 |
Sector | Health | Financials |
52-Week High | $425.64 | $217.87 |
52-Week Low | $179.42 | $145.31 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $56.18B | $738.98B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Royal Bank of Canada (RY) trades at $193.82, up 0.55% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with net income margin improving to 32.01%. Analyst consensus leans neutral with 43% buy ratings while technical indicators show resistance near $194.
RY presents a mixed outlook with robust profitability and dividend stability offset by stretched valuations and bearish technicals. The bank's 18% ROE and U.S. expansion provide upside potential, though high P/E of 17.5 and negative cash flow trends warrant caution. Near-term performance hinges on Q3 earnings due October 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
